Why You Never See A Janus Kinase Inhibitors Market That Actually Works

Janus Kinase (JAK) inhibitors are the drugs that inhibit the abnormal functionality of enzymes in the JAK family such as JAK1, JAK2, JAK3, and TYK2. The inhibition of these enzymes helps interfere with the JAK-STAT signaling pathway, which has been found to play a key role in the development of various autoimmune disorders and cancer indications. Janus Kinase is also found to play a major role in various autoimmune-driven dermatology indications such as alopecia and vitiligo. 

Get Free Sample

Currently, the market has only five approved drugs for the treatment of a few autoimmune and cancer indications. The increasing prevalence of autoimmune disorders and cancer indications has resulted in a high unmet need for treatment using drugs. This is encouraging various vendors and research institutes to conduct research on developing novel Janus Kinase inhibitors in the clinical stages for the treatment of these indications. 

However, a good share of vendors and research institutes that are conducting research are either small or mid-sized companies, which lack the funding to conduct research successfully. So various organizations are also providing funding for the development of novel cancer therapies, including JAK inhibitors. Hence, the increasing research grants are expected to augment the growth of the global Janus kinase inhibitors market at a CAGR of 18.17% during the forecast period. 

Browse Full Report - http://bit.ly/2oKD9yZ